AstraZeneca’s Tozorakimab Hits Phase III Goal in COPD, Marking Third Positive Pivotal Trial

Overview

• Tozorakimab, which met its Phase III goal Monday in the MIRANDA trial, cut the yearly rate of moderate-to-severe COPD exacerbations versus placebo.
• Patients in MIRANDA received 300 mg every two weeks on top of inhaled therapy, with 1,454 former and current smokers enrolled across all eosinophil levels and lung function stages.
• The drug targets IL‑33, a key alarm signal in the airways, which can drive inflammation and thick mucus, offering a new path beyond standard inhalers.
• Investigators reported a favorable safety profile consistent with earlier trials, in what is now the third positive Phase III result for the program after March’s OBERON and TITANIA studies that used monthly dosing.
• AstraZeneca plans to submit the data to regulators and share full results at a medical meeting, a step that could help patients who still face frequent flare-ups despite current care.